Systematic Review and Meta-Analysis of Outcomes of Soluble Guanylate Cyclase Stimulators in Patients With Heart Failure

May 15-17, 2021; Virtual
In patients with heart failure, sGC stimulators reduced risk of a combined endpoint including cardiovascular death and hospitalization for heart failure in individuals with reduced ejection fraction but had no benefit in those with preserved ejection fraction.
Format: Microsoft PowerPoint (.ppt)
File Size: 326 KB
Released: June 28, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck

Related Content

From AHA 2021, new analysis from the CHIEF-HF trial of canagliflozin vs placebo in patients with heart failure, as reported by Clinical Care Options (CCO)

Released: December 3, 2021

From AHA 2021, new analysis from EMPEROR-Preserved trial of empagliflozin in patients with “true” HFpEF, as reported by Clinical Care Options (CCO)

Released: December 2, 2021

From AHA 2021, new analysis of TRED-HF trial on detecting early relapse after HF, as reported by Clinical Care Options (CCO)

Released: December 2, 2021

From Clinical Care Options (CCO), new data in managing heart failure from ACC 2021

Lee R. Goldberg, MD, MPH, FACC James Udelson, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: July 28, 2021 Expired: July 27, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue